Cystamine attenuates the expressions of NOS- and TLR-associated molecules in the brain of NZB/W F1 mice.
Evidence have indicated the impairment of central nervous system (CNS) and neuropsychiatric disorder in patients with systemic lupus erythematosus (SLE). However, little is known to improve the brain abnormality in SLE. To investigate the effect of cystamine on brain abnormality in SLE, NZB/W F1 mice were used as the animal model. Notably, significantly reduced neural Nitric Oxide Synthase (nNOS), inducible Nitric Oxide Synthase (iNOS), p53, p21(WAF1/CIP1), and heat shock protein (HSP)-90 proteins were detected in the brain of NZB/W F1 mice that were treated with cystamine. In contrast, no variation was observed between the brain samples of BALB/c mice that were treated with PBS or cystamine. Moreover, significantly reduced Toll-like receptors- (TLR-) 4, 5 and 7 were detected in the brain samples of NZB/W F1 mice that were treated with cystamine whereas no variation of TLR-4, TLR-5, TLR-7, and TLR-9 was observed in BALB/c mice that were treated with PBS or cystamine. These findings demonstrated the beneficial effects of cystamine on brain abnormality in NZB/W F1 mice and probably suggested the potential of cystamine on treating patients with neuropsychiatric SLE.
Wang
Hon-Pin
HP
Division of Allergy, Rheumatology and Immunology, Department of Internal Medicine, Chia-Yi Christian Hospital, Chia-Yi, Taiwan.
Hsu
Tsai-Ching
TC
Hsu
Gwo-Jong
GJ
Li
Sin-Lun
SL
Tzang
Bor-Show
BS
D000818:Animals; D001921:Brain; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000187:drug effects / Q000378:metabolism; D003538:Cystamine / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D018841:HSP90 Heat-Shock Proteins / Q000187:drug effects / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000503:physiopathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008814:Mice, Inbred NZB; D052248:Nitric Oxide Synthase Type I / Q000187:drug effects / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000187:drug effects / Q000378:metabolism; D051193:Toll-Like Receptors / Q000187:drug effects* / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000187:drug effects / Q000378:metabolism
D050759:Cyclin-Dependent Kinase Inhibitor p21; D018841:HSP90 Heat-Shock Proteins; D051193:Toll-Like Receptors; D016159:Tumor Suppressor Protein p53; D052248:Nitric Oxide Synthase Type I; D052247:Nitric Oxide Synthase Type II; D003538:Cystamine